This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zinapar

Solasia Pharma K.K.

Drug Names(s): ZIO-101, injectable organic arsenical, Darinaparsin (IV), S-dimethylarsino-glutathione, SP-02L

Description: BioMedTracker has separate drug profiles for the IV and oral formulations of ZIO-101. Please also see ZIO-101 (Oral).

ZIO-101 is a small-molecule organic arsenical with potential antineoplastic activity. Although the exact mechanism of action is unclear, darinaparsin, a highly toxic metabolic intermediate of inorganic arsenicals (iAs) that occurs in vivo, appears to generate volatile cytotoxic arsenic compounds when glutathione (GSH) concentrations are low. The arsenic compounds generated from darinaparsin disrupt mitochondrial bioenergetics, producing reactive oxygen species (ROS) and inducing ROS-mediated tumor cell apoptosis; in addition, this agent or its byproducts may initiate cell death by interrupting the G2/M phase of the cell cycle and may exhibit antiangiogenic effects.

Deal Structure: Darinaparsin was originally developed by ZIOPHARM.

ZIOPHARM and Solasia
In January 2011, ZIOPHARM and Solasia Pharma entered into a license and collaboration agreement to develop and commercialize darinaparsin and related organic arsenic molecules in all indications for human use in a pan-Asian/Pacific territory comprised of Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand. ZIOPHARM will receive an up-front payment of $5 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory, and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. ZIOPHARM will also be entitled to receive double digit royalty payments from Solasia on net sales of licensed products in the applicable territories, once commercialized, and a...See full deal structure in Biomedtracker

Partners: ZIOPHARM Oncology, Inc. Meiji Seika Pharma Co., Ltd


Zinapar News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug